Calypte Zahlen WKN 909402 - 500 Beiträge pro Seite

[Insolvenzzocker]

10-Q/A: CALYPTE BIOMEDICAL CORP

(EDGAR Online via COMTEX) -- Results of Operations

The following represents selected financial data:


Three Months Ended Six Months Ended
June 30, June 30,
----------------------- ----------------------
2002 2001 2002 2001
--------- -------- -------- --------
(in thousands) (in thousands)
Total revenue $ 1,209 $ 1,612 $ 2,368 $ 3,014
Product costs 1,397 1,743 3,027 3,732
-- ------ - - ------ - - ------ - - ------ -
Gross Margin (188 ) (131 ) (659 ) (718 )
Operating expenses
Research and development 180 354 421 851
Selling, general and administrative 2,087 2,138 3,302 4,094
-- ------ - - ------ - - ------ - - ------ -
Total operating expenses 2,267 2,492 3,723 4,945
-- ------ - - ------ - - ------ - - ------ -
Loss from operations (2,455 ) (2,623 ) (4,382 ) (5,663 )
Interest income 1 1 2 7
Interest expense (2,492 ) (838 ) (2,539 ) (1,351 )
Other income, net 14 501 22 524
-- ------ - - ------ - - ------ - - ------ -
Loss before income taxes and extraordinary items $ (4,932 ) $ (2,959 ) $ (6,897 ) $ (6,483 )
-- ------ - - ------ - - ------ - - ------ -

Customer Trends

HIV-1 Urine Test Sales Sales of our urine HIV-1 screening test accounted for 29% and 43% of our total sales for the year ended December 31, 2001 and the six months ended June 30, 2002, respectively. Sales of our urine Western Blot supplemental test accounted for approximately 2% of calendar year 2001 revenue and approximately 3% of revenue for the first half of 2002.

Domestic Sales Sales of our HIV-1 screening test to domestic life insurance reference labs accounted for 85% of screening test revenue for calendar year 2001 and for 90% of screening test revenue in the first half of 2002. These reference lab sales are distributed between five labs in 2001 and four in the first half of 2002. LabOne acquired Osborn Laboratories during 2001, resulting in the reduction in the number of reference lab customers. The individual lab sales as a percentage of total reference lab sales range from 6% to 50% in 2001 and from 2% to 50% in the first half of 2002, with LabOne being the largest of the five or four, respectively, in both periods. We market our HIV-1 urine screening test to both the reference labs and to over 100 life insurance companies who have committed to urine testing for HIV screening of at least some of their policy applicants and who employ the labs to conduct their applicant testing. Individual life insurance companies can and do move their business from one lab to another based on a number of considerations, including the availability of urine testing. As the only supplier of an FDA-approved urine based testing algorithm for HIV-1, reference labs must use our testing products to satisfy the demand of insurance companies desiring urine testing. Although Calypte does not expect to lose LabOne or any other reference lab as a customer, should such a loss occur, we believe that its impact would be only short-term, while the insurance companies using urine-based testing in their policy underwriting determinations realigned themselves with another lab offering our urine-based testing algorithm. Direct or distributor sales of our screening test to domestic clinics, public health agencies or community-based organizations were not material in 2001 or in the first half of 2002.

Table of Contents


Dies ist die verkürzte Version...alles unter folgendem LINK: Viel Spass beim übersetzen


http://host.wallstreetcity.com/wsc2/Autoflag.html?Button=Get…

[mfierke]

was soll der alte Scheiß hier, was soll das bewirken????

[Insolvenzzocker]

@ mfierke
wurde aber leider leider vor kurzem veröffentlicht!!

Latest News



2/4/2003 03:34 pm 10-Q/A: CALYPTE BIOMEDICAL CORP

2/4/2003 03:26 pm 10-Q/A: CALYPTE BIOMEDICAL CORP

2/3/2003 07:44 am TheSUBWAY.com Announces Investment Opinion: Monday`s Watch List!

2/3/2003 06:03 am Calypte Comments On President Bush`s Plans for AIDS Relief; Calypte`s Safe Blood for Africa Relationship Focuses on HIV Testing

1/28/2003 07:47 am TheSUBWAY.com Announces Investment Opinion: Stock Watch List!

http://host.wallstreetcity.com/wsc2/Free_RT_Quotes.html?Symb…


Beschwere dich am besten dort....mir ist das meiste auch schon längst bekannt!!!

[loss_pro]

lernt erstma englisch. das sind nur 10Q/As + 10K/As

wer lust hat kann ja die veränderungen raussuchen.

[greyhound_cc]

Mfierke ..noch wach???

...und angriffslustig wie immer!!